30 closest matches · ranked by relevance
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Lung Cancer
Primary: Boost Dose Toxicity — 5 Participants
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Lung Cancer
Primary: Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 2; 1; 1; 1…
Lung Cancer
Primary: Overall Survival at 2 Years — 36.60 percentage of participants
Lung Cancer
Primary: Overall Survival (12-month Rate Reported) — 60.1; 50.8 percentage of participants — p=0.2103
Lung Cancer
Primary: Local Control at 2 Years — 97.6 percentage of subjects — p=0.013
Extensive Stage Small Cell Lung Carcinoma · Limited Stage Small Cell Lung Carcinoma
Primary: Number of Participants With Deterioration in HVLT-R Delayed Recall Score at Six Months (Phase III) — 33; 27 Participants — p=0.28
Limited Stage Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 14.5; 10.7 months
Lung Cancer
Primary: Counts of ≥ Grade 3 Adverse Events (AE) Graded by CTCAE v4 (Common Terminology Criteria for Adverse Events) That Are Definitely, Probably, or Possibly Related to…
Lung Cancer
Primary: Primary Tumor Control at 2 Years — 96.2 percentage of patients
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST) — 11; 2 percentage of participants
Lung Cancer
Primary: Number of Participants With Overall Survival (OS) at 3 Years — 31; 70 Participants
Lung Cancer
Primary: Incidence of AE Grade 3 or Higher Toxicity — 24; 26 Participants
Stage IV Non-Small Cell Lung Cancer
Primary: Progression Free Survival — 3.5; 9.7 months — p=.01
Small Cell Lung Cancer
Primary: 8-Week Progression-Free Rate — 0.0; 8.3 percentage of participants
Lung Cancer
Primary: (Phase I) Maximum Tolerated Dose of Stereotactic Body Radiotherapy (SBRT) as Assessed by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v4.0 — 12.0 Gy/FX
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Progression-free Survival (PFS) — 5.5; 4.9 months — p=0.17
Extensive Stage Small Cell Lung Cancer
Primary: Percentage of Participants Alive and Progression-free (PF) at 6 Months — 30.2 Percentage of Participants
Small Cell Lung Cancer
Primary: Overall Survival — 8.1; 10.6 months — p=<0.01
Small Cell Lung Cancer · Extensive-stage Small Cell Lung Cancer
Primary: Phase I: Confirmation of Recommended Phase II Dose — 3; 1 mg/kg dose
Lung Cancer
Primary: Time to Local Recurrence — NA; NA years — p=0.98
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Small Cell Lung Cancer
Primary: Part A: Percentage of Participants Achieving an Overall Response (Overall Response Rate) — 2.6 percentage of participants
Lung Cancer
Primary: Overall Survival (OS) of Nivolumab + Ipilimumab Versus Placebo In The Global Population — 9.56; 9.17 Months — p=0.3693
Limited Stage Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 12.6; 13.2; 9.5 Months
Lung Cancer
Primary: Patient Response — 2; 1; 2; 27 participants
Small Cell Lung Cancer
Primary: Time to Disease Progression - Median Time to Progression and Log-Rank Test — 5.68; 5.62 Months — p=0.10
Small Cell Lung Cancer
Primary: Determine the Proportion of Previously Treated Small Cell Lung Cancer (SCLC) Patients Whose Disease Has Not Progressed Following 6-weeks (2 Cycles) of Treatment With…
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants